WO2004111208A1 - Celulas madres derivadas de cartilago y sus aplicaciones - Google Patents
Celulas madres derivadas de cartilago y sus aplicaciones Download PDFInfo
- Publication number
- WO2004111208A1 WO2004111208A1 PCT/ES2004/070041 ES2004070041W WO2004111208A1 WO 2004111208 A1 WO2004111208 A1 WO 2004111208A1 ES 2004070041 W ES2004070041 W ES 2004070041W WO 2004111208 A1 WO2004111208 A1 WO 2004111208A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- isolated
- cell population
- characteristic
- stem cells
- Prior art date
Links
- 210000000845 cartilage Anatomy 0.000 title claims description 21
- 210000000130 stem cell Anatomy 0.000 title description 55
- 210000004027 cell Anatomy 0.000 claims abstract description 204
- 238000000034 method Methods 0.000 claims abstract description 41
- 210000001612 chondrocyte Anatomy 0.000 claims abstract description 36
- 210000004504 adult stem cell Anatomy 0.000 claims abstract description 22
- 239000000427 antigen Substances 0.000 claims abstract description 11
- 102000036639 antigens Human genes 0.000 claims abstract description 11
- 108091007433 antigens Proteins 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 16
- 239000002831 pharmacologic agent Substances 0.000 claims description 15
- -1 CDllb Proteins 0.000 claims description 14
- 239000003124 biologic agent Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 13
- 210000000988 bone and bone Anatomy 0.000 claims description 11
- 230000003902 lesion Effects 0.000 claims description 11
- 210000003205 muscle Anatomy 0.000 claims description 11
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 10
- 210000001188 articular cartilage Anatomy 0.000 claims description 10
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 208000016361 genetic disease Diseases 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 10
- 239000003102 growth factor Substances 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 9
- 102000019034 Chemokines Human genes 0.000 claims description 8
- 108010012236 Chemokines Proteins 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 8
- 238000010171 animal model Methods 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 210000003491 skin Anatomy 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 239000007943 implant Substances 0.000 claims description 6
- 210000002569 neuron Anatomy 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000002254 cytotoxic agent Substances 0.000 claims description 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 239000003471 mutagenic agent Substances 0.000 claims description 5
- 231100000707 mutagenic chemical Toxicity 0.000 claims description 5
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 4
- 102100024210 CD166 antigen Human genes 0.000 claims description 4
- 102100032912 CD44 antigen Human genes 0.000 claims description 4
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 4
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 4
- 102100037241 Endoglin Human genes 0.000 claims description 4
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 4
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 4
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 4
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 4
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 4
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims description 4
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 claims description 4
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 claims description 4
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 claims description 4
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 4
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 4
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 4
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 4
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 4
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 claims description 4
- 102100025323 Integrin alpha-1 Human genes 0.000 claims description 4
- 102100025305 Integrin alpha-2 Human genes 0.000 claims description 4
- 102100032819 Integrin alpha-3 Human genes 0.000 claims description 4
- 102100032817 Integrin alpha-5 Human genes 0.000 claims description 4
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 4
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 4
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 4
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 4
- 230000036755 cellular response Effects 0.000 claims description 4
- 210000002216 heart Anatomy 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 239000002077 nanosphere Substances 0.000 claims description 4
- 229920001059 synthetic polymer Polymers 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 3
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 102000049320 CD36 Human genes 0.000 claims description 3
- 108010045374 CD36 Antigens Proteins 0.000 claims description 3
- 102100037904 CD9 antigen Human genes 0.000 claims description 3
- 102100023471 E-selectin Human genes 0.000 claims description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 3
- 101000622123 Homo sapiens E-selectin Proteins 0.000 claims description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 3
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 3
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims description 3
- 101001015006 Homo sapiens Integrin beta-4 Proteins 0.000 claims description 3
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 claims description 3
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 claims description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 3
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 3
- 101000622137 Homo sapiens P-selectin Proteins 0.000 claims description 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 3
- 102100022337 Integrin alpha-V Human genes 0.000 claims description 3
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 3
- 102100032999 Integrin beta-3 Human genes 0.000 claims description 3
- 102100033000 Integrin beta-4 Human genes 0.000 claims description 3
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 3
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims description 3
- 102100033467 L-selectin Human genes 0.000 claims description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 3
- 102000003729 Neprilysin Human genes 0.000 claims description 3
- 108090000028 Neprilysin Proteins 0.000 claims description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 3
- 102100023472 P-selectin Human genes 0.000 claims description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 3
- 102100040120 Prominin-1 Human genes 0.000 claims description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 3
- 210000003494 hepatocyte Anatomy 0.000 claims description 3
- 238000010361 transduction Methods 0.000 claims description 3
- 230000026683 transduction Effects 0.000 claims description 3
- 210000001130 astrocyte Anatomy 0.000 claims description 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 210000000107 myocyte Anatomy 0.000 claims description 2
- 210000004248 oligodendroglia Anatomy 0.000 claims description 2
- 210000004409 osteocyte Anatomy 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 2
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 1
- 102100031180 Hereditary hemochromatosis protein Human genes 0.000 claims 1
- 101000993059 Homo sapiens Hereditary hemochromatosis protein Proteins 0.000 claims 1
- 101000866971 Homo sapiens Putative HLA class I histocompatibility antigen, alpha chain H Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 13
- 238000002659 cell therapy Methods 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 30
- 238000002054 transplantation Methods 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 13
- 229930182816 L-glutamine Natural products 0.000 description 13
- 210000002894 multi-fate stem cell Anatomy 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 238000010186 staining Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000007758 minimum essential medium Substances 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010061728 Bone lesion Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100023915 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000009815 adipogenic differentiation Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000009816 chondrogenic differentiation Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007919 intrasynovial administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000009818 osteogenic differentiation Effects 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241001436672 Bhatia Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000008636 Neoplastic Processes Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100001012 cardiac lesion Toxicity 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229920000550 glycopolymer Polymers 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010376 human cloning Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000015357 muscle tissue disease Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Definitions
- the present invention relates to methods for the isolation of adult stem cells, cells isolated by these methods and applications thereof. Specifically, the invention relates to isolated adult stem cells, derived from dedifferentiated chondrocytes, capable of differentiating and giving rise to a series of cell lineages, as well as specific markers present in these cells, such as surface antigens. mobile. Uses for such cells include their use in cell therapy as well as in the search and development of new drugs.
- Organ and tissue transplantation provides a series of promising treatments for various pathologies, making regenerative therapies the central research objective of many biomedicine fields.
- organ and tissue transplantation there are two important problems associated with organ and tissue transplantation. The first and greatest of them is the shortage of donors. Thus, for example, in the US, only 5% of the organs required for transplants are available (Evans et al, 1992).
- stem cells can undergo cell divisions intended for self-maintenance for an unlimited time to originate phenotypic and genotypically identical cells. In addition, they have the ability to differentiate one or several specific cell types from certain signals or stimuli.
- organs and tissues from the patient's own stem cells or from immunocompatible heterologous cells in such a way that the recipient's immune system does not recognize them as foreign, allows a series of associated advantages that solve the problem caused by the Donor shortage and rejection irrigation.
- the use of stem cells for the regeneration of organs and tissues constitutes a promising alternative therapy for various human pathologies, including: concave, bone and muscle lesions, neurodegenerative diseases, immunological rejection, heart diseases and skin disorders (see US patents 5,811. 094, 5,958,767, 6,328,960, 6,379,953, 6,497,875).
- stem cells have many other potential applications related to biomedical technologies that can help facilitate biopharmaceutical research and development activities.
- One of these applications lies in the development of cellular models of human and animal diseases, which can help to substantially improve the speed and efficiency of the search and development processes of new drugs.
- the commonly used way to measure the biological activity of a new compound before entering clinical trials is through incomplete biochemical techniques or expensive and inappropriate ariimal models.
- Stem cells can be a potential source of virtually unlimited amounts of cells, both undifferentiated and differentiated, for in vitro tests aimed at the search and development of new therapeutic compounds (US Patent 6,294,346), as well as to determine their activity, metabolism and toxicity.
- HTS high-throughput screening systems
- Stem cells and their differentiated progeny also have great value in the process of searching and characterizing new genes involved in a wide variety of biological processes, including development, cell differentiation and neoplastic processes (Phillips et al, 2000; amalho - Santos et al, 2002; Ivanova et al, 2002).
- Gene expression systems have already been described for use in combination with cell-based HTS systems (Jayawickreme and Kost, 1997).
- ES cells embryonic stem cells
- adult stem cells Depending on the origin of the stem cells, we can differentiate between embryonic stem cells (ES cells) and adult stem cells.
- ES cells originate from the internal cell mass of the blastocysts and have as their main characteristic the fact of being pluripotential, which means that they can give rise to any adult tissue derived from the three embryonic layers (Evans and Kaufinan, 1981; Thomson et al , 1998; US Patent 6,200,806).
- Adult stem cells are partially compromised cells present in adult tissues, which can remain decades in the human body, although over time they begin to be scarce (Fuchs and Segre, 2002).
- ES cells Despite the high pluripotentiality of ES cells, therapies based on the use of adult stem cells have a number of advantages over those based on ES cells. First, it is difficult to control the culture conditions of ES cells without inducing their differentiation (Thomson et al. 1998), which raises the economic and labor costs necessary for the use of this type of cells. Moreover, ES cells must pass through several intermediate stages before becoming the specific cell type necessary to treat a particular pathology, a process controlled by chemically complex compounds. In addition, there is a strong controversy regarding ES cells due to the widespread belief that human life begins with fertilization, so that the informed consent signed by donors does not eliminate the ethical stigma that involves the use of embryos in research .
- ES cells derived from ES cells are normally subject to rejection by the munologic system because the immunological profile of such cells differs from that corresponding to the recipient.
- therapeutic cloning in which autologous ES cells can be obtained by transferring the nucleus of a patient's somatic cell to the oocyte of a donor woman, this technique has not been developed still in humans and presents serious ethical and legal problems (human cloning is illegal in many countries).
- Another solution could be the generation of "universal" cell lines that have a generalized immune compatibility, but today there is no technology to obtain these cells.
- MPC Multipotent Adult Progenitor Cell
- Cartilage is a tissue composed of a single cellular element, chondrocytes, and an extracellular matrix (ECM) that surrounds chondrocytes. Thanks to this simple structure and cellular composition, cartilage could be a promising potential source of stem cells, in case these cells could be identified and characterized. In addition, the removal of cartilaginous tissue is performed using a non-invasive procedure compared to other procedures (eg bone marrow removal) and poorly contaminated compared to other procedures (eg adipose tissue removal) and without repercussions serious for the patient.
- ECM extracellular matrix
- the adult articular cartilage is avascular, alinfatic, aneural and is nourished from synovial fluid (ankin and Brandt, 1984).
- the only cells present in the articular cartilage are the chondrocytes, responsible for their synthesis, maintenance and renewal of the NDE, which in turn is mainly composed of a network of highly hydrated collagen fibers inserted in a gel of loaded proteoglycans (Maroudas, 1979).
- the digestion of the NDE using collagenase allows the isolation of chondrocytes that can subsequently be grown and expanded in vitro (Mitrovic t ⁇ /., 1979).
- the present invention provides a population of adult multipotent stem cells from mammalian cartilage, preferably from human articular cartilage, isolated and characterized in detail further demonstrating their multipotentiality.
- a first aspect of the invention is to provide an isolated population of multipotent stem cells derived from dedifferentiated chondrocytes, perfectly characterized and free from other cell types.
- said chondrocytes are obtained from human articular cartilage by arthroscopy, which is a routine medical procedure that carries a minimal risk and degree of discomfort for the patient.
- a second aspect of the present invention consists in obtaining in vitro, from said multipotent stem cells derived from dedifferentiated chondrocytes, from differentiated cell populations to various lineages, including but not limited to mesenchymal and neural lineages.
- a third aspect of the invention consists in providing a transgenic cell population, derived from said previously mentioned isolated cells, by modification of their genome.
- a fourth aspect of the invention consists in using the aforementioned isolated cells for the preparation of pharmaceutical compositions that can be used in tissue and organ repair. Said pharmaceutical compositions constitute a further aspect of the present invention.
- a fifth aspect of the invention consists in using the aforementioned isolated cells for the evaluation of the biological activity of different agents in vitro and in vivo.
- Figure 1 is a phase contrast photomicrograph of the stem cells of the present invention.
- Figure 2A shows fluorescence immunocytometry histograms corresponding to positive surface markers in the stem cells of the present invention. Histograms filled in black correspond to the marking with the specific antibody, while the voids correspond to staining with the isotype control.
- Figure 2B shows histograms of fluorescence immunocytometry corresponding to negative surface markers in the stem cells of the present invention. Histograms filled in black correspond to the marking with the specific antibody, while the voids correspond to staining with the isotype control.
- Figure 3A is a phase contrast photomicrograph of the stem cells of the present invention differentiated in vitro to bone phenotype. Differentiated cells have been stained with Alizarin Red to detect the calcium phosphate matrix secreted by differentiated cells.
- Figure 3B is a clear phase contrast photomicrograph of the stem cells of the present invention without differentiation, stained in the same manner as the differentiated cells of Figure 3A.
- Figure 4 ⁇ is a phase contrast photomicrograph of the stem cells of the present invention differentiated in vitro to muscle phenotype. Differentiated cells have been stained with an antibody specific for the myosin heavy chain, a muscle specific antigen.
- Figure 4B is a clear-field photomicrograph of the stem cells of the present invention without differentiation, stained in the same manner as the differentiated cells of Figure 4A.
- Figure 5 A shows two immunofluorescence photomicrographs of the stem cells of the present invention differentiated in vitro towards neuronal phenotype. Differentiated cells have been stained with an antibody specific for NF200, a neuron specific antigen.
- Figure 5B shows two immunofluorescence photomicrographs of the stem cells of the present invention differentiated in vitro towards neuronal phenotype. Differentiated cells have been stained with an antibody specific for TuJl, a neuron specific antigen.
- Figure 7A is a fluorescence photomicrograph of the stem cells of the present invention transduced with a retroviral vector encoding the green fluorescent protein (GFP).
- GFP green fluorescent protein
- Figure 7B shows a fluorescence cytometry histogram that quantifies the fluorescence of retrovirally transduced cells of Figure 7A.
- the present invention provides an isolated population of multipotent stem cells, derived from dedifferentiated mammalian chondrocytes, characterized in detail and free from other cell types.
- the isolated cell population object of the invention comes from the cartilaginous tissue of a primate, preferably from a human.
- the cell object of the invention will come from human articular cartilage and, in particular, from cartilaginous tissue from the knee joint.
- Stem cells and derivatives thereof in the present invention may be used for various applications, including: therapies based on autologous and allogeneic transplantation, development of models of disease, development of gene search trials and drug search and development.
- the invention provides a multipotent adult stem cell, from mammalian dedifferentiated chondrocytes, characterized by being positive for the following surface antigens: CD9, CD13, CD29, CD44,
- CD106 CD166, HLA-I and beta2-microglobulin.
- an isolated multipotent adult stem cell derived from dedifferentiated mammalian chondrocytes is provided, characterized by the following phenotype: positive for markers CD9, CD13, CD29, CD44, CD49a, CD49b, CD49c, CD49e, CD54 , CD55, CD58, CD59, CD90, CD95, CD105, CD106, CD166, HLA-I and beta2-microglobulin; negative for CD10, CDllb, CD14, CD15, CD16, CD18, CD19, CD28, CD31, CD34, CD36, CD38, CD45, CD49d, CD50, CD51, CD56, CD61, CD62E, CD62L, CD62P, CD71, CD102, CD104, CD117, CD133, HLA-II.
- Isolated cell populations constituted by, or comprising, said isolated multipotent adult stem cells from dedifferentiated mammalian chondrocytes, constitute particular embodiments of the present invention.
- the isolated multipotent stem cell object of the present invention is obtained from dedifferentiated adult chondrocytes isolated from cartilage biopsies from living subjects.
- the cartilaginous tissue is isolated from a human subject.
- the preferred source of cartilaginous tissue lies in the knee joint, and the preferred method of collecting cartilage is taking biopsy by arthroscopy from the margins of the femoral condyle.
- the cartilaginous tissue be isolated from that same subject in order to perform an autologous transplant.
- Chondrocytes can be isolated from a cartilage biopsy using various methods known to those skilled in the art. Enzymatic digestion with collagenase is normally used (Mitrovic et al, 1979).
- Example 1 of the present invention details the process of isolating multipotent stem cells from human dedifferentiated chondrocytes obtained from knee articular cartilage.
- Multipotent cells derived from dedifferentiated chondrocytes can be characterized to identify intracellular and / or surface proteins, genes, and / or other markers indicating their undifferentiated state.
- Methods used for characterization include, but are not limited to: immunocytometry (see Example 2), immunocytochemical analysis, northern hlot analysis, RT-PCR, gene expression analysis in microarrays, proteomic studies and differential display analysis.
- the multipotent adult stem cells of the present invention are induced to differentiate in vitro to cells that express at least one characteristic of a specialized cell.
- Such partially or totally differentiated cell types include, but are not limited to cell lines of the following tissues and organs: cartilage, bone, fat, muscle, nerve tissue, skin, liver and pancreas, for example, chondrocytes, osteocytes, adipocytes, myocytes, cardiomyocytes, neurons, astrocytes, oligodendrocytes, epithelial cells, hepatocytes, pancreatic cells, etc.
- the methods that can be used to induce differentiation of the stem cells of the present invention to various specific cell types are known to those skilled in the art and some of them are explained in detail in the Patent Examples.
- Totally or partially differentiated cells are characterized by the identification of surface and / or intracellular proteins, genes, and other markers indicative of differentiation of the stem cells of the present invention to various lineages. Methods used for characterization include, but are not limited to the following: immunocytometry, immunocytochemical analysis, northern blot analysis, RT-PCR, gene expression analysis in microchips, proteomic studies and differential display analysis.
- the stem cells of the present invention, or cells derived therefrom are genetically modified in a stable or transient manner so that they express exogenous genes or repress the expression of endogenous genes.
- the invention provides an isolated transgenic cell population, derived from multipotent adult stem cells from dedifferentiated mammalian chondrocytes provided by this invention, whose genome has been modified by inserting preselected isolated DNA, by replacing a segment of the cell genome. with pre-selected isolated DNA or by inactivation of at least a portion of the cellular genome.
- the isolated cells are contacted with a gene transfer vector, which comprises a nucleic acid that includes a recombinant heterologous genetic sequence, such that the nucleic acid is introduced into the cell under the appropriate conditions for said sequence to be expressed inside the cell.
- the gene transfer vector can be viral or non-viral.
- Viral vectors suitable for practicing this embodiment of the invention include, but are not limited to the following: adenoviral vectors (Kozarsky and Wilson, 1993), adeno-associated vectors (Muzyczka, 1992), retroviral vectors (Tabin et al, 1982), lentiviral vectors (Naldini et al, 1996), alpha-viral vectors (Huang, 1996), herpesvrral vectors (Carpenter and Stevens, 1996) and coronavirus-derived vectors (Ortego et al, 2002).
- Non-viral type vectors suitable for practicing this embodiment of the invention include, but are not limited to the following: naked DNA (Wolff et al, 1990), gene gun (Johnston et al, 1988), liposomes (Felgner et al , 1987), polyamines (Boussif et al, 1995), peptides (Wyman et al, 1997), dendrimers (Tang et al, 1996), canon glycopolymers (Roche et al, 2003), liposome-polycation complexes (Tsai et al, 1996), proteins (Fisher and Wilson, 1997) and receptor-mediated gene transfer systems (Cotten et al, 1990).
- the recombinant heterologous genetic sequence is normally included in an expression cassette, which consists of a coding sequence operatively associated with a promoter or other cis sequences that allow its expression.
- the coding sequence can encode a protein or it can encode biologically active RNA, such as antisense RNA (Spampinato et al, 1992), a ribozyme (Leavitt et al, 1994) or siRNA (Qin et al, 2003).
- the stem cells of the present invention are genetically modified to express a potentially therapeutic gene.
- the stem cells of the present invention can be used to prepare pharmaceutical compositions.
- the cells of the present invention may be used alone or within biologically compatible compositions, which may include, but are not limited to: growth factors, cytokines, chemokines, extracellular matrix proteins, synthetic drugs and polymers. Therefore, in a particular embodiment of this invention, a pharmaceutical composition is provided which comprises a population of stem cells provided by the present invention, unmodified or genetically modified, or expressing at least one characteristic of a specialized, unmodified cell. or genetically modified, and a pharmaceutically acceptable vehicle.
- said pharmaceutical composition may also contain growth factors, cytokines, chemokines, extracellular matrix proteins, drugs and / or synthetic polymers.
- the pharmaceutical compositions prepared from the cells of the present invention have the form of a three-dimensional structure in which the cells and other possible components are included within a biocompatible three-dimensional synthetic matrix.
- said pharmaceutical compositions are of the microparticle, microsphere, nanoparticle or nanosphere type.
- the implants described above can be used in autologous and allogeneic transplant procedures. These transplant procedures can be carried out by administering the implants to a patient in various ways. Preferred forms of administration include but are not limited to: parenteral, intraperitoneal, intravenous, intradermal, epidural, intraspinal, intrastromal, intraarticular, intrasynovial, intrathecal, intralesional, intraarterial, intracardiac, intramuscular, intranasal, intracranial, subcutaneous, intraorbital, intracapsular, topical, through transdermal patches, rectal, vaginal or urethral, through the administration of a suppository, percutanea, nasal spray, surgical implant, internal surgical paint, infusion pump or route catheter.
- the place of transplantation is cartilage, and the desired characteristic or phenotype is the chondroblastic.
- the site of transplantation is the bone, and the desired characteristic or phenotype is the osteoblastic.
- the site of transplantation is the skeletal muscle, and the desired characteristic or phenotype is the myoblastic.
- the place of transplantation is the cardiac muscle, and the desired characteristic or phenotype is the cardiomyoblastic.
- the site of transplantation is the peripheral nervous system, and the desired characteristic or phenotype is the glial.
- the place of transplantation is the central nervous system, and the desired characteristic or phenotype is the neuronal.
- the site of transplantation is the skin, and the desired characteristic or phenotype is the epithelial.
- the site of transplantation is the liver, and the desired characteristic or phenotype is the hepatocyte.
- the site of transplantation is the liver, and the desired characteristic or phenotype is that of a pancreatic cell.
- the place of transplantation is the pancreas, and the desired characteristic or phenotype is that of a pancreatic cell.
- the preferred therapeutic use of the cells described in the present invention is intended to be the treatment of degenerative, traumatic, genetic, infectious or neoplastic diseases that result in damage or dysfunction of tissues or organs that include, but are not limited to: fistulas, ulcers, cartilage lesions, bone lesions, muscle injuries, muscle disorders (including, but not limited to muscular dystrophy), bone diseases (including, but not limited to osteogenesis imperfecta), myocardial lesions, neurodegenerative disorders (including, but not be limited to: Parson inson disease, Huntington's disease and Alzheimer's disease), spinal injuries, damage nervous, vascular lesions, skin lesions, liver damage and diabetes.
- degenerative diseases that result in damage or dysfunction of tissues or organs that include, but are not limited to: fistulas, ulcers, cartilage lesions, bone lesions, muscle injuries, muscle disorders (including, but not limited to muscular dystrophy), bone diseases (including, but not limited to osteogenesis imperfecta), myocardial lesions, neurodegenerative disorders (including, but not be limited to
- Preferred embodiments of the genetically modified cells of the invention include, but are not limited to: enzyme replacement therapy, replacement of damaged cells and tissues, correction of deleterious genetic mutations, antiangiogenic therapy, proangiogenic therapy, anti-inflammatory therapy, release of bioactive compounds and release of antitumor agents.
- the invention relates to the use of a population of stem cells provided by the present invention, unmodified or genetically modified, or expressing at least one characteristic of a specialized, unmodified or genetically modified cell. modified, to prepare a pharmaceutical composition for the treatment of lesions, degenerative and genetic diseases of cartilage, bone, muscle, heart, central and peripheral nervous system, skin, liver and pancreas.
- said isolated cell population provided by this invention can be used to prepare a pharmaceutical composition suitable for the treatment of cartilage lesions, or bone lesions, or muscle lesions, or cardiac lesions, or nervous system lesions.
- the presence in the subject, to which the transplant has been performed, of differentiated cells from the multipotent isolated stem cells of the present invention could be detected by various techniques, including but not limited to: in vivo image , flow cytometric analysis, PCR analysis, southern blot analysis and immunohistochemical studies.
- the stem cells of the present invention with or without genetic modifications, as well as cells derived from the above that express at least one characteristic of a specialized cell, with or without genetic modifications, can be applied.
- in vitro and in vivo tests with the following industrial purposes: drug search, pharmacological studies, toxicological studies, pharmacogenomic studies and genetic studies.
- assays can be used for the identification and / or characterization of a multitude of biological targets, bioactive compounds or pharmacological agents.
- the stem cells of the present invention provide a unique system in which cells can be differentiated to give rise to specific lineages of the same individual.
- the cells of the present invention provide a source of cells in culture from a potential variety of genetically diverse individuals that can respond differently to various biological and pharmacological agents. By comparing the responses of cells from a statistically significant population of individuals, the effects of the biological or pharmacological agents tested on the specific cell type can be determined.
- the cells of the present invention can be maintained in culture and thus can be studied as time goes by. Therefore, multiple cell cultures of the same or different individuals can be treated with the agent of interest to determine if there are differences in the effect that said agent has on certain cell types with the same genetic profile or, alternatively, on similar cell types.
- stem cells of the present invention in a high-throughput screening system makes it possible to analyze a wide range of biological and pharmacological agents, as well as combinatorial libraries thereof, in an effective way in terms of time and money, in this way elucidate its effects on human cells.
- agents include, but are not limited to: peptides, antibodies, cytokines, chemokines, growth factors, hormones, viral particles, antibiotics, inhibitory compounds, chemotherapeutic agents, cytotoxic agents, mutagens, food additives, pharmaceutical compositions and vaccine preparations.
- the stem cells of the present invention isolated from a statistically significant population of individuals can be used to provide an ideal system for identifying polymorphisms associated with positive or negative responses to a range of substances.
- the information obtained from these studies can have wide repercussions in the treatment of infectious diseases, cancer and various metabolic diseases.
- the in vitro method that allows the use of the stem cells of the present invention to evaluate the cellular response to biological or pharmacological agents, or to combinatorial libraries of said agents, comprises the following:
- stem cells provided by the present invention optionally genetically modified, or cells expressing at least one characteristic of a specialized cell, optionally genetically modified, can be used.
- the biological or pharmacological agents that can be evaluated include, but are not limited to, peptides, antibodies, cytokines, chemokines, growth factors, viral particles, hormones, drugs, for example, antibiotics, chemotherapeutic agents, cytotoxic agents, pharmaceutical compositions, vaccine preparations, extracellular matrix proteins, synthetic polymers, inhibitory compounds, mutagens, food additives, etc.
- the in vivo method that allows the use of the stem cells of the present invention to evaluate the cellular response to biological or pharmacological agents, or to combinatorial libraries of said agents, comprises the following:
- stem cells provided by the present invention optionally genetically modified, or cells expressing at least one characteristic of a specialized cell, optionally genetically modified, can be used.
- the experimental animal may be, but is not limited to, an immunodeficient mouse strain.
- biologically compatible compositions may include, but are not limited to, the following types of substances: peptides, antibodies, cytokines, chemokines, growth factors, viral particles, hormones, drugs, for example, antibiotics, chemotherapeutic agents, cytotoxic agents, pharmaceutical compositions, vaccine preparations, extracellular matrix proteins, synthetic polymers, inhibitory compounds, mutagens, food additives, etc.
- the cells are implanted in the experimental animal included in a synthetic matrix. three-dimensional biocompatible.
- the cells are introduced into the animal included in a structure of the microparticle, microsphere, nanoparticle or nanosphere type. Preferred forms of implantation of said cells, compositions and structures in the experimental animal include but are not limited to the following: parenteral, intraperitoneal, intravenous, intradermal, epidural, intraspinal, intrastromal, intraarticular, intrasynovial, intrathecal, intralesional, intraarterial, intracardiac.
- Example 1 Isolation of multipotent stem cells derived from dedifferentiated chondrocytes obtained from human articular cartilage. It begins by obtaining a cartilage biopsy of the external margins of the femoral condyle by arthroscopic procedure. The size of this biopsy can vary, depending on the structure of the joint, the age of the patient and the surgeon's criteria, but usually it is not less than 4 cm 2 . The biopsy is collected in a sterile saline solution and kept at 4 ° C until the moment of processing, which should not be later than 48 hours after taking the sample.
- the cartilage biopsy is suspended in 1 milliliter of sterile basal culture medium (DMEM, Minimum essential medium modified by Dulbecco), containing 2 mM L-Glutamine, antibiotics and 1% bovine fetal serum (FBS).
- the serum may also be of human origin, preferably of autologous origin.
- the cartilage is crushed using surgical scissors under aseptic conditions.
- the resulting cartilage fragments are added to a suspension containing 0.1% collagenase in the same medium that was used for crushing, and the resulting cell suspension is incubated for at least 4 hours at 37 ° C with gentle agitation.
- the resulting cell suspension is filtered through a sterile 40 micrometer mesh and then the filtered suspension is centrifuged at 500 g for 5 minutes.
- the resulting cell pellet is resuspended in culture medium and grown at an approximate density of 20,000 cells / cm 2 in tissue culture jars.
- the culture medium is composed of a basal medium such as DMEM, 2 mM L-Glutamine, 10% FBS and antibiotics (Choi et al, 1980; Webber and Sokoloff, 1981).
- DMEM basal medium
- FBS FBS
- antibiotics Choi et al, 1980; Webber and Sokoloff, 1981.
- Another possibility is to use human serum from an autologous source, instead of bovine serum.
- a defined culture medium which contains a basal medium such as DMEM, RPMI, F12 or a combination thereof, 2 mM L-Glutamine, antibiotics, and a supplementary medium that includes, but is not limited to, the following: insulin, transferrin, selenium, albumin and linoleic acid (Kato et al, 1980; Schwartz and Sugumaran, 1982; Jennings et al, 1983; Adolphe et al, 1984; Quarto et al, 1997; US Patent 6,150,163) .
- a basal medium such as DMEM, RPMI, F12 or a combination thereof
- 2 mM L-Glutamine antibiotics
- a supplementary medium that includes, but is not limited to, the following: insulin, transferrin, selenium, albumin and linoleic acid (Kato et al, 1980; Schwartz and Sugumaran, 1982; Jennings et al, 1983; Adolphe et
- the cells are grown in an incubator at 37 ° C with 5% CO 2 and 95% humidity. After four days in culture, the medium is removed, the non-adherent cells are removed by washing with phosphate buffered saline (PBS) and fresh medium is added. After another four days, the cells are washed again and detached by incubating them with a solution containing 0.25% trypsin and 0.02% EDTA (ethylenediaminetetraacetic acid). The detached cells are centrifuged to precipitate them and grown at a density of 5,000 cells / cm 2 in new culture jars.
- PBS phosphate buffered saline
- EDTA ethylenediaminetetraacetic acid
- the cells in monolayer culture are maintained in a state of subconfluence by their detachment and reoccurrence at 5,000 cells / cm 2 .
- the resulting adherent cells are multipotent isolated stem cells that can be maintained dedifferentiated under the culture conditions described above.
- Figure 1 shows a photomicrograph of said cells, after 15 days in culture.
- Example 2 Immunophenotypic characterization of multipotent stem cells derived from human dedifferentiated chondrocytes.
- Stem cells derived from dedifferentiated chondrocytes are collected by gentle digestion with trypsin, washed with PBS and incubated for 30 minutes at 4 ° C with one of the following antibodies labeled with FITC or PE: CD9, CD10, CDllb, CD13, CD14, CD15 , CD16, CD18, CD19, CD28, CD29, CD31, CD34, CD36, CD38, CD44, CD45, CD49a, CD49b, CD49c, CD49d, CD49e, CD50, CD51, CD54, CD55, CD56, CD58, CD59, CD61, CD62E , CD62L, CD62P, CD71, CD90, CD95, CD102, CD104, CD105, CD106, CD117, CD133, CD166, HLA-I, HLA-II and beta2-microglobulin.
- the labeled cells are washed and analyzed immediately using an Epics-XL cytometer (Coulter). As controls, cells stained with nonspecific antibodies of the corresponding fluorescein-labeled isotypes (FITC) or phycoerythrin (PE) were used.
- Figure 2A shows the histograms that indicate a positive mareaje of the cells, while Figure 2B shows the histograms that indicate the absence of the corresponding antigen.
- Example 3 In vitro differentiation of multipotent stem cells derived from human dedifferentiated chondrocytes to bone phenotype cells.
- Stem cells derived from dedifferentiated chondrocytes are seeded at a density of 20,000 cells / cm 2 in standard culture medium (DMEM, 10% FBS, 2 mM L-Glutamine and antibiotic). At 12 hours the culture medium is replaced by means of osteogenesis inducer (Jaiswal et al, 1997) composed of:
- Example 4 In vitro differentiation of multipotent stem cells derived from human dedifferentiated chondrocytes to muscle phenotype cells.
- DMEM dedifferentiated chondrocytes
- Example 5 In vitro differentiation of multipotent stem cells derived from human dedifferentiated chondrocytes to neuronal phenotype cells.
- Stem cells derived from dedifferentiated chondrocytes are plated in 96-well plates at the rate of one cell per well, applying the limit dilution method, in standard culture medium (DMEM, 10% FBS, 2 mM L-Glutamine and antibiotic).
- DMEM standard culture medium
- FBS fetal bovine serum
- 2 mM L-Glutamine antibiotic-free bovine serum
- antibiotic antibiotic-free bovine serum
- the cultures are allowed to evolve until a high cellular confluence is reached, making changes of culture medium twice a week.
- the clones are subcultured on a larger surface as a high cellular confluence is reached. The cloning efficiency is between 50-60%. There are no morphological differences between the different clones obtained. Once the clones have been expanded, it is carried out with the same osteogenic, adipogenic and chondrogenic differentiation.
- Adipogenic differentiation Stem cells derived from dedifferentiated chondrocytes are seeded at a density of 20,000 cells / cm 2 in standard culture medium (DMEM, 10% FBS, 2 mM L-Glutamine and antibiotic). At 12 hours the adipogenesis inducing medium is added (Pittenger et al, 1999) composed of:
- the blocks with the included samples are cut to a thickness of 4 ⁇ m with a microtome.
- staining with Alcian Blue (Lev et al, 1964) is performed as detailed below: the samples are dewaxed and hydrated and stained with an Alcian Blue solution prepared in 0.1 N hydrochloric acid for 30 minutes; then they are dehydrated again and mounted with a resinous medium.
- Alcian Blue solution prepared in 0.1 N hydrochloric acid for 30 minutes
- sulfated proteoglycans stained blue can be visualized.
- immunofluorescence was performed against the type II collagen molecule, which is expressed by chondrocytic cells, being one of the main components of the extracellular matrix of cartilage.
- Example 7 Expression by retroviral transduction of a heterologous gene in multipotent stem cells derived from human dedifferentiated chondrocytes.
- GFP expression can be analyzed by fluorescence microscopy (see Figure 7A) or by flow cytometry (see Figure 7B).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/560,354 US20060239980A1 (en) | 2003-06-12 | 2004-06-09 | Cartilage-derived stem cells and applications thereof |
CA002528679A CA2528679A1 (en) | 2003-06-12 | 2004-06-09 | Cartilage-derived stem cells and applications thereof |
EP04742080A EP1632563A1 (en) | 2003-06-12 | 2004-06-09 | Cartilage-derived stem cells and applications thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200301386 | 2003-06-12 | ||
ES200301386A ES2265199B1 (es) | 2003-06-12 | 2003-06-12 | Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004111208A1 true WO2004111208A1 (es) | 2004-12-23 |
Family
ID=33547858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2004/070041 WO2004111208A1 (es) | 2003-06-12 | 2004-06-09 | Celulas madres derivadas de cartilago y sus aplicaciones |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060239980A1 (es) |
EP (1) | EP1632563A1 (es) |
CA (1) | CA2528679A1 (es) |
ES (1) | ES2265199B1 (es) |
WO (1) | WO2004111208A1 (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007039150A2 (en) * | 2005-09-23 | 2007-04-12 | Cellerix, S.L. | Cell populations having immunoregulatory activity, method for isolation and uses |
US10548924B2 (en) | 2004-08-25 | 2020-02-04 | Tigenix, S.A.U. | Use of adipose tissue-derived stromal stem cells in treating fistula |
US11273182B2 (en) | 2016-03-14 | 2022-03-15 | Takeda Pharmaceutical Company Limited | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
US7833709B2 (en) | 2004-05-28 | 2010-11-16 | Wafergen, Inc. | Thermo-controllable chips for multiplex analyses |
ES2313805B1 (es) * | 2004-10-04 | 2009-12-23 | Cellerix, S.L. | Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral. |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
EP1764117A1 (en) | 2005-09-20 | 2007-03-21 | Zimmer GmbH | Implant for the repair of a cartilage defect and method for manufacturing the implant |
EP2087098A4 (en) * | 2006-11-09 | 2010-03-31 | Univ Johns Hopkins | DEDIFFERENTIATION OF ADULT MAMMALIAN CARDIOMYCYTES INTO CARDIAC STEM CELLS |
GB0702401D0 (en) | 2007-02-08 | 2007-03-21 | Univ Cardiff | Connective tissue repair |
US8563307B2 (en) | 2009-02-24 | 2013-10-22 | James Wang | Treatment of immunosuppression-related disorders |
US8323972B2 (en) | 2009-09-30 | 2012-12-04 | Advanced Technologies And Regenerative Medicine, Llc | Mammary artery derived cells and methods of use in tissue repair and regeneration |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US8679474B2 (en) | 2010-08-04 | 2014-03-25 | StemBios Technologies, Inc. | Somatic stem cells |
TWI571513B (zh) | 2011-09-28 | 2017-02-21 | 幹細胞生物科技股份有限公司 | 體幹細胞及其製備方法 |
WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
JP6433896B2 (ja) | 2012-08-13 | 2018-12-05 | シーダーズ−サイナイ・メディカル・センターCedars−Sinai Medical Center | 組織再生のためのエキソソームおよびマイクロリボ核酸 |
JP5856029B2 (ja) * | 2012-08-31 | 2016-02-09 | 阿部 博幸 | 間葉系幹細胞を未分化増殖させる方法、および間葉系幹細胞を濃縮する方法 |
US10724005B2 (en) | 2012-09-28 | 2020-07-28 | Scripps Health | Methods of differentiating stem cells into chondrocytes |
JP6399558B2 (ja) * | 2012-10-29 | 2018-10-03 | スクリップス ヘルス | 軟骨細胞から多能性幹細胞を製造する方法 |
US9974885B2 (en) | 2012-10-29 | 2018-05-22 | Scripps Health | Methods of transplanting chondrocytes |
JP6495174B2 (ja) | 2012-12-06 | 2019-04-03 | ステムバイオス テクノロジーズ,インコーポレイテッド | Lgr5+体性幹細胞 |
EP2746770A1 (en) | 2012-12-21 | 2014-06-25 | Stembios Technologies, Inc. | Method for evaluating effect of action on subject based on stem celldynamics |
JP6878274B2 (ja) | 2014-10-03 | 2021-05-26 | シーダーズ−サイナイ・メディカル・センターCedars−Sinai Medical Center | 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム |
CN106573018A (zh) * | 2014-11-19 | 2017-04-19 | 干细胞生物科技公司 | 用于治疗骨骼缺损的体干细胞 |
WO2016134342A1 (en) * | 2015-02-20 | 2016-08-25 | Wafergen, Inc. | Method for rapid accurate dispensing, visualization and analysis of single cells |
EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
WO2018017892A1 (en) | 2016-07-21 | 2018-01-25 | Takara Bio Usa, Inc. | Multi-z imaging and dispensing with multi-well devices |
US11541078B2 (en) | 2016-09-20 | 2023-01-03 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
EP3612191A4 (en) | 2017-04-19 | 2020-12-30 | Cedars-Sinai Medical Center | METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCLE DYSTROPHY |
EP3727351A4 (en) | 2017-12-20 | 2021-10-06 | Cedars-Sinai Medical Center | MODIFIED EXTRACELLULAR VESICLES FOR IMPROVED TISSUE DELIVERY |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001011011A2 (en) * | 1999-08-05 | 2001-02-15 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
WO2002010348A2 (en) * | 2000-07-29 | 2002-02-07 | Smith & Nephew Plc | Tissue implant for cartilage repair |
-
2003
- 2003-06-12 ES ES200301386A patent/ES2265199B1/es not_active Withdrawn - After Issue
-
2004
- 2004-06-09 US US10/560,354 patent/US20060239980A1/en not_active Abandoned
- 2004-06-09 EP EP04742080A patent/EP1632563A1/en not_active Withdrawn
- 2004-06-09 CA CA002528679A patent/CA2528679A1/en not_active Abandoned
- 2004-06-09 WO PCT/ES2004/070041 patent/WO2004111208A1/es active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001011011A2 (en) * | 1999-08-05 | 2001-02-15 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
WO2002010348A2 (en) * | 2000-07-29 | 2002-02-07 | Smith & Nephew Plc | Tissue implant for cartilage repair |
Non-Patent Citations (3)
Title |
---|
ARAI F. ET AL.: "Mesenchymal stem cells in perichodrium express activated leucocyte cell adhesion molecule and participate in bone marrow formation", J. EXP. MED., vol. 195, no. 12, 17 June 2002 (2002-06-17), pages 1549 - 1563, XP002982870 * |
BARBERO A. ET AL.: "PLasticity of clonal populations of differentiated adult human articular chodrocytes", ARTHRITIS RHEUM., vol. 48, no. 5, May 2003 (2003-05-01), pages 1315 - 1325, XP008041995 * |
DE BARI C. ET AL.: "Multipotent mesenchymal stem cells from adult human synovial membrane", ARTHRITIS RHEUM., vol. 44, no. 8, August 2001 (2001-08-01), pages 1928 - 1942, XP002266867 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10548924B2 (en) | 2004-08-25 | 2020-02-04 | Tigenix, S.A.U. | Use of adipose tissue-derived stromal stem cells in treating fistula |
US10780132B2 (en) | 2004-08-25 | 2020-09-22 | Tigenix, S.A.U. | Use of adipose tissue-derived stromal stem cells in treating fistula |
US10758575B2 (en) | 2005-06-24 | 2020-09-01 | Tigenix, S.A.U. | Use of adipose tissue-derived stromal stem cells in treating fistula |
US11660318B2 (en) | 2005-06-24 | 2023-05-30 | Takeda Pharmaceutical Company Limited | Use of adipose tissue-derived stromal stem cells in treating fistula |
US11672831B2 (en) | 2005-06-24 | 2023-06-13 | Takeda Pharmaceutical Company Limited | Use of adipose tissue-derived stromal stem cells in treating fistula |
WO2007039150A2 (en) * | 2005-09-23 | 2007-04-12 | Cellerix, S.L. | Cell populations having immunoregulatory activity, method for isolation and uses |
WO2007039150A3 (en) * | 2005-09-23 | 2007-08-23 | Cellerix Sl | Cell populations having immunoregulatory activity, method for isolation and uses |
EP2340847A3 (en) * | 2005-09-23 | 2016-11-09 | Cellerix, S.A. | Cell populations having immunoregulatory activity, method for isolation and uses |
US9943550B2 (en) | 2005-09-23 | 2018-04-17 | Tigenix, S.A.U. | Cell populations having immunoregulatory activity, method for isolation and uses |
US11273182B2 (en) | 2016-03-14 | 2022-03-15 | Takeda Pharmaceutical Company Limited | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease |
Also Published As
Publication number | Publication date |
---|---|
ES2265199A1 (es) | 2007-02-01 |
CA2528679A1 (en) | 2004-12-23 |
EP1632563A1 (en) | 2006-03-08 |
ES2265199B1 (es) | 2008-02-01 |
US20060239980A1 (en) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2265199B1 (es) | Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones. | |
ES2535042T3 (es) | Identificación y aislamiento de células multipotentes de tejido mesenquimal no osteocondral | |
US7534606B2 (en) | Placental stem cell and methods thereof | |
ES2287447T3 (es) | Metodos de aislamiento y expansion del cultivo de celulas troncales/madre mesenquimatosas a partir de sangre del cordon umbilical, y metodo de diferenciacion de celulas troncales/madre mesenquimatosas derivadas de sangre del cordon umbilical en diversos tejidos mesenquimatosos. | |
Nery et al. | Human mesenchymal stem cells: from immunophenotyping by flow cytometry to clinical applications | |
EP2374871B1 (en) | Pluripotent stem cells, method for preparation thereof and uses thereof | |
ES2870567T3 (es) | Células madre procedentes de una capa trofoblástica coriónica pura y terapia celular que comprende las mismas | |
KR100871984B1 (ko) | 태반 조직 유래 다능성 줄기세포 및 이를 함유하는세포치료제 | |
Jackson et al. | Mesenchymal progenitor cells derived from traumatized human muscle | |
KR101158473B1 (ko) | 연골줄기세포를 유효성분으로 포함하는 골질환 치료용 또는 항염증용 약제학적 조성물 | |
US7781211B2 (en) | Isolation of multi-lineage stem cells | |
WO2007010858A1 (ja) | 骨格筋組織由来の単一細胞よりクローン化した多能性幹細胞 | |
US20190194611A1 (en) | Method for culturing differentiation-promoting and -sustaining spheroid form of tonsil-derived stem cells | |
CN105814196A (zh) | 终末分化的神经元谱系的获得方法及其用途 | |
ES2360434B1 (es) | Celulas madre pluripotenciales obtenidas a partir de la pulpa dental. | |
CN104946590A (zh) | 成人骨髓中Muse细胞诱导为神经前体细胞的方法 | |
WO2012133942A1 (ja) | 生体の臍帯又は脂肪組織から単離できる多能性幹細胞 | |
US8796020B2 (en) | Manufacturing process for fresh and frozen stem cells | |
EP2615166B1 (en) | Equine amniotic fluid derived multipotent stem cells and a production method therefor | |
KR20140016841A (ko) | 태아연골조직유래 줄기세포원 및 이를 포함하는 세포치료제 | |
US20080299656A1 (en) | Isolation of multi-lineage stem cells | |
Yu | Identification and characterization of cartilage progenitor cells by single cell sorting and cloning | |
ES2706376T3 (es) | Procedimiento para obtener una población de células progenitoras estrómicas | |
WO2010112662A1 (es) | Células madre multipotentes derivadas de estroma de mesenterio | |
Yameen et al. | Multilineage differentiation potential of bone and cartilage cells derived from explant culture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004742080 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2528679 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2004742080 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006239980 Country of ref document: US Ref document number: 10560354 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10560354 Country of ref document: US |